« Return to News | Study Conduct

Australian doctors discover disparities in cancer research

Tuesday, April 19, 2011 11:35 AM

Doctors in Australia, in a study conducted by the University of Sydney, revealed some serious disparities in cancer research.  The study indicates few clinical trials target four of the most serious types of cancer, according to a report in the Sydney Morning Herald.

Of 386 recent interventional cancer trials recruiting patients in Australia, only 24 focused on lung cancer, despite it being one of the deadliest variants, the study found.

Medical oncologist Rachel Dear and her co-authors also found few trials being designed for the study of colorectal, prostate and pancreatic cancers, three other lethal forms of the Breast cancer accounted for 62 of the trials.

Dear used data from the Australian New Zealand Clinical Trials Registry to explore the number and types of cancer clinical trial activity.

"We found that the number of trials for each cancer type did not always match the burden of disease caused by that cancer, thereby identifying gaps in cancer research," Dear said.

Her research is published in the Medical Journal of Australia.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.